Thematic hub | Healthcare | Biotech

What are biotech stocks?

Biotechnology stocks include companies that develop innovative medical treatments, diagnostic tools, and healthcare technologies.

With ADSS, investors can access and invest in biotechnology stocks with zero commission.

Open account

Unlike traditional pharmaceutical companies, that focus on chemical-based drug development, biotechnology firms use advanced techniques including genetic engineering, cell therapy, immunotherapy, and molecular biology to create breakthrough treatments for previously untreatable conditions. The biotechnology sector covers a broad spectrum of companies, from gene therapy developers and cancer immunotherapy specialists through to medical device manufacturers and healthcare technology platforms.

This business model relies heavily on scientific innovation and intellectual property protection, with companies often founded around breakthrough research discoveries from academic institutions or corporate laboratories. These businesses typically operate with longer development timelines than traditional pharmaceuticals, as many biotechnology treatments involve complex biological mechanisms that require extensive research and clinical validation.

The sector includes both therapeutic biotechnology companies that develop treatments for specific diseases, and platform biotechnology firms that create enabling technologies used by other healthcare companies. Typically, biotech stocks are more focused in their treatment areas than classic pharmaceutical companies, and accordingly offer a more volatile risk profile; however, many pharmaceutical companies are also involved in biotech, and the two subsectors are closely linked.

What are thematic stocks?

Investing in biotechnology stocks

Biotechnology stocks offer investors exposure to growth themes, with the potential for significant returns from new treatments and treatment types, designed to address unmet medical needs. Like pharmaceuticals stocks, their eventual products will be under patent for 20 years and the firm must recuperate the development cost in that period; however, compared to traditional drug discovery, research costs in biotech are considerably higher. These companies often demonstrate binary risk-reward profiles, where successful clinical trials and regulatory approvals can lead to dramatic share price appreciation, whilst negative trial results or regulatory setbacks can cause severe stock declines. A comparable stock sector is technology, though biotech is less concentrated in large, diversified companies. Investing in biotech carries significant risks, and this subsector is highly volatile and requires significant subject knowledge to invest prudently. However, like most healthcare stocks, demand for biotech products does not follow overall economic growth, so life sciences and biotechnology stocks may also offer some defensive benefits in periods of recession.

Sector Highlights

Global market size: The size of the global biotech market was estimated at $1.6 trillion in 2023, with 648 US biotechnology stocks for a total market capitalisation of $808 billion. Estimates on the size of the biotech market vary considerably due to the difficulties in identifying the exact boundary between traditional pharma stocks and biotechnology.
Top stocks: Moderna, Gilead Sciences, Amgen
Important themes: Biological technology, drug pricing, AI

Browse all sectors

Important biotech stocks

Pricing from TradingView is indicative and does not represent ADSS pricing.

Open an account and start investing with ADSS today

Open account

Market trends impacting biotech stocks

The biotechnology sector faces market pressures that differ significantly from traditional pharmaceutical companies, though, like their mainstream equivalents, stock performance is heavily influenced by clinical trial outcomes and regulatory decisions. Since biotech companies are involved in creating entirely new therapies, technological developments in biological treatments are the most important driver in stock performance. Unlike established drug manufacturers with diversified product portfolios, biotechnology stocks typically depend on smaller numbers of experimental treatments, creating concentrated risk and reward scenarios that drive volatile share price movements. Even amongst tech stocks, such a concentrated focus on a single product is rare, making these some of the most volatile stocks, with enormous potential for growth alongside a high downside risk.

Get started with
ADSS today

Opening an account with ADSS in 3 easy steps.

Start investing

Register

Submit online application (UAE residents can apply with UAE Pass)

Fund

Fund using Mastercard, VISA, UAEPGS (for UAE bank accounts holders only)

Invest

Invest in biotech stocks through the ADSS platform

FAQs

What makes biotech stocks different from other healthcare investments?

Biotech stocks include companies focused on medical innovation using new biological techniques like gene therapy or immunotherapy, rather than traditional based drug development. Unlike established pharmaceutical companies with diverse product portfolios, biotech companies typically concentrate on breakthrough treatments for specific diseases, making them more volatile but potentially more rewarding investments. These life sciences companies often operate with longer development timelines and higher research costs, as they’re pioneering entirely new therapeutic approaches that require extensive clinical validation before reaching the market.

Are biotechnology investments suitable for all investors?

Biotechnology investments carry significant risks due to their dependence on clinical trial outcomes and regulatory approvals, making them less suitable for risk-averse investors. A single biotech company might see dramatic stock price swings based on trial results for just one or two experimental treatments, leading to a scenario where success can lead to substantial gains while failure can result in severe losses. However, for investors with appropriate risk tolerance and subject knowledge, biotech stocks offer exposure to medical innovation and healthcare technology advancement, with the defensive benefit that demand for life-saving treatments remains relatively stable regardless of economic conditions.

How can investors evaluate different types of biotech stocks?

Investors should consider the various subsectors within biotechnology, including gene therapy stocks, immunotherapy stocks, and medical device stocks, each with distinct risk profiles and growth potential. When evaluating a biotech company, key factors include the strength of their intellectual property portfolio, the stage of their clinical trials, their cash runway for continued research, and the size of the market for their targeted treatments. Since biotechnology stocks are among the most volatile investments, diversification across multiple biotech companies and thorough research into their specific therapeutic areas and competitive advantages are essential for managing risk while capturing the growth potential of medical innovation.